drugset / Trial / NCT00542893

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

NCT00542893

Phase 1 Completed Genta Incorporated
RandomizedCrossoverOpen-labelTreatment

Summary

This clinical drug-drug interaction study is being conducted to evaluate the pharmacokinetics of dacarbazine(DTIC) when administered in combination with Genasense

Timeline

Start
2006-04
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule 1000 mg/m2
Subject oblimersen sodium Antisense oligonucleotide 7 mg/kg

Indications